Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

WCCS/EADO 2016 | The use of photopheresis for the treatment of cutaneous T-cell lymphoma

Robert Knobler, MD of the Medical University of Vienna, Vienna, Austria talks about extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma (the particular varient being Sézary syndrome) at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. Extracorporeal photopheresis was invented in 1983 and became well known worldwide in 1987 when the first study was published in the New England Journal of Medicine. Prof. Knobler’s role was to review the literature and the progress that has been done in the past 30 years in the use of this therapy. The literature of over 37 published papers (review articles and retrospective studies) have been reviewed and it has been found that the efficacy of this therapy, which was shown to be significant in inducing complete remission (CR) in refactory patients as well as patients who were responding to other therapies but not optimally, has been reproduced in over 1200 patients that were treated with this technology. The complete remission (CR) rates and response rates fluctuate around the same numbers as in the New England Journal of Medicine. He goes on to explain that the side effect profile of this treatment is extremely low and that is why the therapy is attractive for these patients. There has been an increase in studies from the US and Europe trying to figure out how this therapy works. This is because, even though it is a very simple therapy based on dermatological photochemotherapy, we still do not understand the mechanisms of action completely. He explains that during this treatment the combination of UVA light and psoralen induceds apoptosis and the introduction of apoptopic cells into the bloodstream enhances and provokes an immune response which seems to assist the body to contol the disease known as Sézary syndrome. He explains that the European Organisation for Research and Treatment of Cancer (EORTC) is in the process of organizing a prospective one arm trial to test the recommendations of the European Dermatology Forum guidelines on how exactly to use this therapy in treating these patients.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.